FOXO4

Compound Overview

FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 transcription factors. In senescent-cell research models, FOXO4 binds p53 to prevent apoptosis. Disrupting this interaction with FOXO4-DRI allows researchers to study p53-triggered apoptosis in senescent cells while sparing normal cells, making it a research tool for selective senolysis.

Research Background & Published Literature

A Cell publication from Baar et al. (2017), authored by researchers at Erasmus University Medical Center, demonstrated selective elimination of senescent cells in aged mouse models and helped drive broader interest in senolytics research.

Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:

• Baar et al. (2017) — Cell
• Alameen et al. (2026) — Naunyn Schmiedebergs Arch Pharmacol

Storage, Handling & Stability Guidelines

Use the applicable lot/source record for storage of unopened material. Any diluent selection, preparation, temperature, aliquoting, or post-reconstitution hold conditions must be established by a qualified laboratory under a validated SOP; this page does not establish a stability window.

• Keep ambient-temperature handling time as short as practical to support compound integrity.
• Reseal vials promptly after each withdrawal to limit moisture exposure.
• Use appropriate personal protective equipment and follow institutional chemical safety protocols at all times.
• For traceability, label aliquots with compound name, concentration, reconstitution date, and operator initials.

Quality Assurance & Lab Verification

A finalized public Certificate of Analysis is available for this catalog item. Review the public COA for the applicable lot. Lot-specific identifiers, assay values, and methods are maintained in that record and are not repeated in this product dossier.